We are busy preparing for the Annual Industry kickoff conference at the Westin in San Francisco. Currently, we are scheduling 30-minute meetings on behalf of our clients. Plus, we're planning…
As 2011 draws to a close, here are a few thoughts on 2011 and 2012: Uncertainty - If there is one word that captures the mood of the year, it…
Lacerta Bio was privileged to give a short talk at the first (and hopefully annual) Drug Delivery Summit in London late last month. While lightly attended, the two-day conference brought…
Pharmaceutical outsourcing to CROs is certainly nothing new. However, this week we learned that pharmaceutical giant Lilly and AMRI signed an interesting insourcing / outsourcing agreement. In this deal, AMRI…
Lacerta Bio was pleased to take part in a terrific overview of technologies for oral delivery of peptides and proteins: The oral delivery of biopharmaceuticals is highly desirable because it…
This week, our good "acquaintances" from EBD Group launched partnering360. What is it? According to EBD: partnering360™ is an online network of professionals in the life science industry, emerging from…
Lacerta Bio spent the week at the AAPS ( American Association of Pharmaceutical Scientists ) annual conference . Over 8,000 pharmaceutical scientists, service providers, and others came to AAPS in…
Call us late to the party, but in August of this year, KPMG published Future Pharma: Five Strategies to Accelerate the Transformation of Pharmaceutical Industry... The entire report is available…
In our view, there are two basic types of biotech business development-related due diligence. The first is external , where the team gathers and analyzes data about a target company…
In a few weeks, Lacerta Bio will return to DC to participate in the annual convention and celebrate the 25th anniversary of the American Association of Pharmaceutical Scientists (AAPS). AAPS…